-+ 0.00%
-+ 0.00%
-+ 0.00%

MiNK Therapeutics Q2 FY26 net loss narrows to $3.13 million; cash falls to $8.81 million

PUBT·08/13/2026 11:31:55
Listen to the news
MiNK Therapeutics Q2 FY26 net loss narrows to $3.13 million; cash falls to $8.81 million
  • Mink Therapeutics posted a Q2 net loss of USD 3.13 million, narrowing from USD 4.24 million a year earlier.
  • Loss per share improved to USD 0.62 from USD 1.06 in the prior-year quarter.
  • Cash and cash equivalents fell to USD 8.81 million at June 30 from USD 13.36 million at Dec. 31.
  • Cash used in operations rose to USD 2.08 million from USD 1.57 million a year earlier.
  • Randomized Phase 2 C-1300-02 trial in acute lung injury initiated in May; initial Day 28 observations showed survival and improved oxygenation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130730PRIMZONEFULLFEED9809055) on August 13, 2026, and is solely responsible for the information contained therein.